A. Gnani

发表

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

M. Baccarani, P. Piccaluga, M. Rondoni, 2007, Haematologica.

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.

M. Baccarani, P. Piccaluga, M. Rondoni, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.

G. Rosti, S. Soverini, R. Bassan, 2012, Leukemia research.

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

M. Baccarani, S. Paolini, G. Rosti, 2009, Blood.

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

M. Baccarani, G. Rosti, G. Martinelli, 2011, Leukemia research.

Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML.

M. Baccarani, G. Rosti, G. Martinelli, 2005 .

Mitoxantrone: an effective drug in advanced breast cancer in the elderly Proposal of a self compilation questionnaire for weekly determination of subjective status in elderly patients Somatostatin and/or octreotide eased treatments: an Italian institutional dilemma also for geriatric patients

F. Leoncini, M. Aragona, S. Novelli, 2005 .

IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis

M. Baccarani, G. Martinelli, M. Delledonne, 2011, Leukemia.

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

M. Baccarani, G. Rosti, G. Martinelli, 2006, Clinical Cancer Research.

Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).

M. Baccarani, P. Piccaluga, M. Rondoni, 2006 .

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

R. Foà, M. Baccarani, A. Vitale, 2011, Haematologica.

Interferon‐alpha may restore sensitivity to tyrosine‐kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation

M. Baccarani, G. Martinelli, M. Luppi, 2009, British journal of haematology.

Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors.

M. Baccarani, M. Rondoni, S. Paolini, 2007 .

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.

M. Baccarani, M. Rondoni, S. Paolini, 2007, The Lancet. Oncology.

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

M. Baccarani, M. Rondoni, S. Paolini, 2008 .

Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party

R. Foà, R. Fanin, M. Baccarani, 2008 .

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

M. Baccarani, S. Paolini, G. Rosti, 2009, Blood.

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.

G. Rosti, S. Soverini, R. Bassan, 2012, Leukemia research.

In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.

M. Baccarani, G. Rosti, G. Martinelli, 2007 .